Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
March 2024 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
February 2024 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
I found out last week that I am not only in a complete remission, but also there was no measurable CLL in my peripheral blood done by flow cytometry, down to 1 in 10,000 cells
A newly published paper in JAMA Oncology found that among cancer patients with suspected ibrutinib-related cardiotoxic effects, the presence of heart muscle injury and scarring is high, and this is associated with an increased risk of developing future cardiovascular adverse events.
Dr. Ed Ratner’s Review of For Blood and Money by Nathan Vardi that chronicles the development of two blockbuster drugs
Over the course of a year of monthly meetings, the CLL Bloodline will teach the BASICS needed to understand CLL, bring news, help with the acronyms and new vocabulary, and offer
One click to our most popular content.
